CA2828713C - Alkyne substituted quinazoline compounds and methods of use - Google Patents

Alkyne substituted quinazoline compounds and methods of use Download PDF

Info

Publication number
CA2828713C
CA2828713C CA2828713A CA2828713A CA2828713C CA 2828713 C CA2828713 C CA 2828713C CA 2828713 A CA2828713 A CA 2828713A CA 2828713 A CA2828713 A CA 2828713A CA 2828713 C CA2828713 C CA 2828713C
Authority
CA
Canada
Prior art keywords
compound
cancer
salt
solvate
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2828713A
Other languages
English (en)
French (fr)
Other versions
CA2828713A1 (en
Inventor
Wang Shen
Aimin Zhang
Jack Maung
Xiaoling Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NewGen Therapeutics Inc
Original Assignee
NewGen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NewGen Therapeutics Inc filed Critical NewGen Therapeutics Inc
Publication of CA2828713A1 publication Critical patent/CA2828713A1/en
Application granted granted Critical
Publication of CA2828713C publication Critical patent/CA2828713C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2828713A 2011-03-04 2012-03-02 Alkyne substituted quinazoline compounds and methods of use Active CA2828713C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161449088P 2011-03-04 2011-03-04
US61/449,088 2011-03-04
PCT/US2012/027614 WO2012122058A2 (en) 2011-03-04 2012-03-02 Alkyne substituted quinazoline compound and methods of use

Publications (2)

Publication Number Publication Date
CA2828713A1 CA2828713A1 (en) 2012-09-13
CA2828713C true CA2828713C (en) 2022-08-16

Family

ID=46798728

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2828713A Active CA2828713C (en) 2011-03-04 2012-03-02 Alkyne substituted quinazoline compounds and methods of use

Country Status (14)

Country Link
US (5) US9090588B2 (enExample)
EP (1) EP2680850B1 (enExample)
JP (1) JP6006242B2 (enExample)
KR (4) KR20200003933A (enExample)
CN (1) CN103998040B (enExample)
AU (3) AU2012225693A1 (enExample)
BR (1) BR112013022552B1 (enExample)
CA (1) CA2828713C (enExample)
IL (1) IL228072A (enExample)
MX (1) MX344302B (enExample)
RU (1) RU2013144571A (enExample)
SG (3) SG10201601711SA (enExample)
TW (1) TWI617556B (enExample)
WO (1) WO2012122058A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012225693A1 (en) 2011-03-04 2013-09-19 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
JP6437820B2 (ja) * 2011-07-27 2018-12-12 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド キナゾリン誘導体、その製造方法、中間体、組成物及びその適用
CN104119350B (zh) 2013-04-28 2017-04-12 广东东阳光药业有限公司 氨基喹唑啉类衍生物及其盐和使用方法
CN103254156B (zh) * 2013-05-10 2015-08-26 苏州明锐医药科技有限公司 阿法替尼中间体的制备方法
CN103254183B (zh) * 2013-05-10 2015-11-11 苏州明锐医药科技有限公司 阿法替尼的制备方法
TWI740873B (zh) 2015-12-24 2021-10-01 日商協和麒麟股份有限公司 α、β不飽和醯胺化合物
DE102016224889B4 (de) * 2016-12-14 2019-11-07 Airbus Defence and Space GmbH Verfahren zur Vorbeugung einer Ablösung einer Fluidströmung, Strömungskörpersystem und Luftfahrzeug
US11083492B2 (en) * 2018-06-06 2021-08-10 Lifetech Scientific (Shenzhen) Co., Ltd Method for implanting an interventional medical device
US10973321B2 (en) 2018-09-04 2021-04-13 Steelcase Inc. Workspace system and components and method for the use thereof
WO2020068867A1 (en) 2018-09-25 2020-04-02 Black Diamond Therapeutics, Inc. Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
WO2021030711A1 (en) * 2019-08-15 2021-02-18 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
CN113527215B (zh) * 2020-04-17 2023-12-05 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、制备方法及其应用
WO2021209039A1 (zh) * 2020-04-17 2021-10-21 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、制备方法及其应用
KR20230093429A (ko) * 2020-11-02 2023-06-27 블랙 다이아몬드 테라퓨틱스, 인코포레이티드 알킨 치환된 퀴나졸린 유도체로 암을 치료하는 방법
CN120769850A (zh) * 2023-03-02 2025-10-10 江苏康缘药业股份有限公司 一种炔基取代的喹唑啉化合物的晶型、其制备方法和应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4062881A (en) 1974-07-26 1977-12-13 Cincinnati Milacron Chemicals, Inc. Sulfide containing tin stabilizers
US4343940A (en) 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
GB2160201B (en) 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
EP0326307B1 (en) 1988-01-23 1994-08-17 Kyowa Hakko Kogyo Co., Ltd. Novel pyridazinone derivatives and pharmaceutical preparations containing them
US5053227A (en) 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
JP3089901B2 (ja) 1993-07-20 2000-09-18 株式会社豊田自動織機製作所 クラッチレス圧縮機における動力伝達構造
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9405355D0 (en) 1994-03-18 1994-05-04 Lucas Ind Plc Vibrating element transducer
WO1996029331A1 (de) 1995-03-20 1996-09-26 Dr. Karl Thomae Gmbh Imidazochinazoline, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE69522717T2 (de) 1995-03-30 2002-02-14 Pfizer Inc., New York Chinazolinderivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
CA2194756A1 (en) 1995-05-12 1996-11-14 Jun Yuan Novel deazapurine derivatives; a new class of crf1 specific ligands
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
EP0832073B1 (en) 1995-06-07 2002-01-16 Sugen, Inc. Quinazolines and pharmaceutical compositions
CA2223081C (en) 1995-06-07 2001-03-06 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
ATE212993T1 (de) 1995-07-06 2002-02-15 Novartis Erfind Verwalt Gmbh Pyrolopyrimidine und verfahren zu ihrer herstellung
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
WO1997038973A1 (en) 1996-04-16 1997-10-23 Ube Industries, Ltd. Hydrazine compounds, process for the preparation thereof, and insecticides for agricultural and horticultural use
JP4386967B2 (ja) 1996-07-13 2009-12-16 グラクソ、グループ、リミテッド プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
ATE309225T1 (de) 1998-07-30 2005-11-15 Wyeth Corp Substituierte chinazoline derivate
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6627634B2 (en) 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
IL153111A0 (en) 2000-06-30 2003-06-24 Glaxo Group Ltd Quinazoline ditosylate salt compounds
ATE321556T1 (de) 2000-10-27 2006-04-15 Novartis Pharma Gmbh Behandlung gastrointestinaler stroma-tumoren
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CA2442742A1 (en) 2001-02-21 2002-08-29 Mitsubishi Pharma Corporation Quinazoline derivatives
TW200813014A (en) 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
GB0215823D0 (en) * 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
EP2280003B1 (en) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
JP4353903B2 (ja) 2005-01-07 2009-10-28 東京エレクトロン株式会社 クラスタツールの処理システム
JP2008545688A (ja) * 2005-05-25 2008-12-18 ワイス 置換３−シアノキノリン並びにその中間体を合成する方法
JP5688877B2 (ja) * 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌疾患の治療用キナゾリン誘導体
EP1981863B1 (en) 2006-01-26 2012-10-10 Boehringer Ingelheim International GmbH Process for preparing aminocrotonylamino-substituted quinazoline derivatives
CN100345856C (zh) 2006-03-10 2007-10-31 武汉化工学院 一种制备葡萄糖醛酸内酯的酯化及结晶工艺方法
JP5580592B2 (ja) 2006-09-11 2014-08-27 キュリス，インコーポレイテッド 亜鉛結合部分を含むキナゾリン系ｅｇｆｒインヒビター
AU2008233930A1 (en) 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
WO2011084796A2 (en) 2009-12-21 2011-07-14 Qiang Zhang Novel quinazoline derivatives
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN102382106A (zh) 2010-08-30 2012-03-21 黄振华 苯胺取代的喹唑啉衍生物
AU2012225693A1 (en) 2011-03-04 2013-09-19 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途

Also Published As

Publication number Publication date
BR112013022552B1 (pt) 2021-11-23
TW201249835A (en) 2012-12-16
KR20220031732A (ko) 2022-03-11
JP6006242B2 (ja) 2016-10-12
US9090588B2 (en) 2015-07-28
CN103998040A (zh) 2014-08-20
WO2012122058A3 (en) 2014-04-24
US20160031860A1 (en) 2016-02-04
KR20200003933A (ko) 2020-01-10
TWI617556B (zh) 2018-03-11
EP2680850A2 (en) 2014-01-08
MX344302B (es) 2016-12-13
US20210047303A1 (en) 2021-02-18
SG193291A1 (en) 2013-10-30
CN103998040B (zh) 2017-03-29
US11524956B2 (en) 2022-12-13
SG10201913982WA (en) 2020-03-30
US20190382382A1 (en) 2019-12-19
SG10201601711SA (en) 2016-04-28
IL228072A (en) 2016-08-31
EP2680850B1 (en) 2018-05-23
KR20140020955A (ko) 2014-02-19
WO2012122058A2 (en) 2012-09-13
US20180093975A1 (en) 2018-04-05
KR20210043016A (ko) 2021-04-20
BR112013022552A2 (pt) 2016-12-06
MX2013010016A (es) 2013-11-20
RU2013144571A (ru) 2015-04-10
AU2018267622A1 (en) 2018-12-13
JP2014518544A (ja) 2014-07-31
US20140128417A1 (en) 2014-05-08
CA2828713A1 (en) 2012-09-13
EP2680850A4 (en) 2015-01-28
AU2012225693A1 (en) 2013-09-19
IL228072A0 (en) 2013-09-30
AU2018267622B2 (en) 2020-05-14
KR102061743B1 (ko) 2020-01-03
AU2017200984A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
AU2018267622B2 (en) Alkyne substituted quinazoline compound and methods of use
RU2650895C2 (ru) Соединения замещенных пиразолонов и способы использования
JP5721709B2 (ja) リンを含むキナゾリン化合物および使用方法
JP2024512624A (ja) Ｍｅｋ阻害剤としての３，４－ジヒドロ－２，７－ナフチリジン－１，６（２ｈ，７ｈ）－ジオン
JP2022500379A (ja) 組み合わせ療法
US9187459B2 (en) Quinazoline-7-ether compounds and methods of use
CN115701996A (zh) 用于治疗EGFR突变型NSCLC的CBP/p300溴结构域抑制剂和EGFR抑制剂的组合
CN103717590B (zh) 喹唑啉-7-醚化合物及使用方法
US20230000876A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
JP2020524659A (ja) 化合物
RU2826000C1 (ru) 3,4-дигидро-2,7-нафтиридин-1,6(2h,7h)-дионы в качестве ингибиторов mek

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180228

EEER Examination request

Effective date: 20180228

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217